Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $2.8 million.

  • Ligand Pharmaceuticals' Other Non-Current Assets fell 6702.76% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 6702.76%. This contributed to the annual value of $6.9 million for FY2024, which is 832.29% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Other Non-Current Assets of $2.8 million as of Q3 2025, which was down 6702.76% from $9.1 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Other Non-Current Assets ranged from a high of $270.8 million in Q4 2021 and a low of $1.7 million during Q4 2022
  • For the 5-year period, Ligand Pharmaceuticals' Other Non-Current Assets averaged around $20.1 million, with its median value being $6.4 million (2023).
  • Per our database at Business Quant, Ligand Pharmaceuticals' Other Non-Current Assets soared by 624598.08% in 2021 and then plummeted by 9935.89% in 2022.
  • Ligand Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $270.8 million in 2021, then plummeted by 99.36% to $1.7 million in 2022, then surged by 268.2% to $6.4 million in 2023, then rose by 8.32% to $6.9 million in 2024, then tumbled by 59.98% to $2.8 million in 2025.
  • Its Other Non-Current Assets stands at $2.8 million for Q3 2025, versus $9.1 million for Q2 2025 and $7.9 million for Q1 2025.